Fallopian Tube Carcinoma

Categories: Cancer diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Fallopian Tube Carcinoma

MalaCards integrated aliases for Fallopian Tube Carcinoma:

Name: Fallopian Tube Carcinoma 12 55 15 17 72
Fallopian Tube Cancer 12 53 37 55 15
Cancer of the Fallopian Tube 12 53
Carcinoma of Fallopian Tube 12 29
Neoplasm of Fallopian Tube 12 29
Fallopian Tube Neoplasms 44 72
Malignant Neoplasm of Fallopian Tube 72
Malignant Neoplasm of Uterine Tube 12
Malignant Tumour of Fallopian Tube 12
Malignant Tumor of Fallopian Tubes 59
Malignant Tumor of Fallopian Tube 12
Tumor, Fallopian Tube, Malignant 12
Tumor of the Fallopian Tube 12
Cancer of Fallopian Tubes 59
Fallopian Tube Neoplasm 12
Malignant Tubal Tumor 59
Fallopian Tube Ca 12
Tubal Cancer 59


Orphanet epidemiological data:

malignant tumor of fallopian tubes
Prevalence: 1-9/100000 (Europe);


External Ids:

Disease Ontology 12 DOID:1963 DOID:1964
KEGG 37 H01554
ICD9CM 35 183.2
MeSH 44 D005185
SNOMED-CT 68 93794008
ICD10 33 C57.0
ICD10 via Orphanet 34 C57.0
UMLS via Orphanet 73 C0153579 C0238122
Orphanet 59 ORPHA180242
UMLS 72 C0015558 C0153579 C0238122

Summaries for Fallopian Tube Carcinoma

NIH Rare Diseases : 53 Fallopian tube cancer develops in the tubes that connect a woman's ovaries and uterus. It is very rare and accounts for only 1-2% of all gynecologic cancers. Fallopian tube cancer occurs when normal cells in one or both tubes change and grow in an uncontrolled way, forming a mass called a tumor. Cancer can begin in any of the different cell types that make up the fallopian tubes. The most common type is called adenocarcinoma (a cancer of cells from glands). Leiomyosarcoma (a cancer of smooth muscle cells) and transitional cell carcinoma (a cancer of the cells lining the fallopian tubes) are more rare. While some fallopian tube cancers actually begin in the tubes themselves, fallopian tube cancer is more often the result of cancer spreading from other parts of the body to the tubes. For example, the fallopian tubes are a common site of metastasis (spread) of cancers that started in the ovaries, uterus, endometrium, (the tissue lining the uterus) appendix, or colon. Women with fallopian tube cancer may experience symptoms, although some affected women may have no symptoms at all. The signs of fallopian tube cancer are often non-specific, meaning that they can also be signs of other medical conditions that are not cancer. Signs and symptoms of fallopian tube cancer can include: irregular or heavy vaginal bleeding (especially after menopause); occasional abdominal or pelvic pain or feeling of pressure; vaginal discharge that may be clear, white, or tinged with blood; and a pelvic mass or lump. Doctors use many tests to diagnose cancer of the fallopian tubes. Some of these tests may include: pelvic examination, transvaginal ultrasound, a blood test that measures the tumor marker CA-125, computed tomography (CT or CAT) scan, and magnetic resonance imaging (MRI). Fallopian tube cancer can be best treated when detected early. If the cancer has spread to the walls of the tubes or outside of the tubes, then there is a lower chance that the disease can be treated successfully. The stage of the cancer determines the type of treatment needed. Most women will need surgery and some will go on to have chemotherapy and/or radiation therapy.

MalaCards based summary : Fallopian Tube Carcinoma, also known as fallopian tube cancer, is related to fallopian tube adenocarcinoma and tuberculous salpingitis. An important gene associated with Fallopian Tube Carcinoma is BRCA1 (BRCA1 DNA Repair Associated), and among its related pathways/superpathways are Gene Expression and Cell Cycle, Mitotic. The drugs Olaparib and Poly(ADP-ribose) Polymerase Inhibitors have been mentioned in the context of this disorder. Affiliated tissues include ovary, breast and testes, and related phenotypes are Decreased homologous recombination repair frequency and Decreased homologous recombination repair frequency

Disease Ontology : 12 A female reproductive organ cancer that is located in fallopian tube.

KEGG : 37
Fallopian tube cancer is a rare, aggressive gynecologic malignancy. Recent genetic and immunohistochemical studies strongly suggest that high-grade serous adenocarcinoma (SAC) involving the ovary likely arises from distal fallopian tube epithelium, indicating that some ovarian cancers develop in the fallopian tube and are then spread to the ovary. Fallopian tube cancers are similar to ovarian cancer with respect to the proportion of tumors with abnormal expression of c-erbB-2 and p53. It has been proposed that the p53 signature is the earliest step in the pathogenesis of fallopian tube cancer. In this model, tubal epithelium on the fimbria experiences genotoxic damage and, as a result, the secretory cell exhibits over-accumulation of p53 protein (p53 signature). There is also some evidence that BRCA-1 and BRCA-2 mutations and c-myc have a major role in tumorgenesis.

Wikipedia : 75 Primary fallopian tube cancer (PFTC), often just tubal cancer, is a malignant neoplasm that originates... more...

Related Diseases for Fallopian Tube Carcinoma

Diseases related to Fallopian Tube Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 231)
# Related Disease Score Top Affiliating Genes
1 fallopian tube adenocarcinoma 32.9 ERBB2 BRCA2 BRCA1
2 tuberculous salpingitis 30.7 ERBB2 BRCA2 BRCA1
3 inflammatory breast carcinoma 30.6 PGR ERBB2
4 papillary serous adenocarcinoma 30.6 TP53 PGR BRCA1
5 carcinosarcoma 30.6 TP53 PGR ERBB2
6 in situ carcinoma 30.5 TP53 PGR ERBB2 BRCA1
7 serous cystadenocarcinoma 30.5 VEGFA TP53 PGR ERBB2
8 papillary adenocarcinoma 30.4 TP53 PGR ERBB2
9 estrogen-receptor positive breast cancer 30.4 TP53 PGR ERBB2
10 ovarian serous cystadenocarcinoma 30.4 TP53 PGR ERBB2
11 uterine carcinosarcoma 30.3 TP53 PGR ERBB2
12 cystadenocarcinoma 30.0 VEGFA TP53 PGR ERBB2
13 wilms tumor 1 29.8 TP53 PGR ERBB2 BRCA2
14 endometrial adenocarcinoma 29.8 VEGFA TP53 PGR ERBB2
15 primary peritoneal carcinoma 29.2 VEGFA TP53 PGR ERBB2 BRCA2 BRCA1
16 endometrial cancer 29.1 VEGFA TP53 PGR ERBB2 BRCA2 BRCA1
17 ovarian cancer 27.8 VEGFA TP53 RAD51D PGR ERBB2 BRCA2
18 breast cancer 26.9 VEGFA TP53 RAD51D PGR ERBB2 BRCA2
19 familiar fallopian tube carcinoma 12.5
20 fallopian tube adenosarcoma 11.4
21 fallopian tube transitional cell carcinoma 11.4
22 fallopian tube squamous cell carcinoma 11.4
23 fallopian tube leiomyosarcoma 11.4
24 fallopian tube carcinosarcoma 11.4
25 fallopian tube germ cell cancer 11.4
26 ovarian epithelial cancer 10.6
27 gastric papillary adenocarcinoma 10.6 TP53 ERBB2
28 pleomorphic adenoma carcinoma 10.6 TP53 ERBB2
29 endometrium carcinoma in situ 10.6 TP53 PGR
30 non-proliferative fibrocystic change of the breast 10.5 TP53 ERBB2
31 breast squamous cell carcinoma 10.5 TP53 ERBB2
32 breast apocrine carcinoma 10.5 PGR ERBB2
33 scirrhous adenocarcinoma 10.5 PGR ERBB2
34 glassy cell carcinoma of the cervix 10.5 PGR ERBB2
35 glioma susceptibility 1 10.5 TP53 ERBB2
36 breast malignant phyllodes tumor 10.5 TP53 PGR
37 intracystic papillary adenoma 10.5 PGR ERBB2
38 breast metaplastic carcinoma 10.5 PGR ERBB2
39 esophagus adenocarcinoma 10.5 TP53 ERBB2
40 breast scirrhous carcinoma 10.5 PGR ERBB2
41 olfactory groove meningioma 10.5 TP53 PGR
42 progesterone-receptor negative breast cancer 10.5 PGR ERBB2
43 vaginal discharge 10.5
44 hereditary site-specific ovarian cancer syndrome 10.5 BRCA2 BRCA1
45 progesterone-receptor positive breast cancer 10.5 PGR ERBB2
46 bartholin's gland disease 10.5 TP53 PGR
47 cervical carcinosarcoma 10.5 TP53 PGR
48 apocrine adenocarcinoma 10.5 PGR ERBB2
49 female reproductive endometrioid cancer 10.5 TP53 PGR
50 rare tumor 10.5

Comorbidity relations with Fallopian Tube Carcinoma via Phenotypic Disease Network (PDN):

Ovarian Cancer

Graphical network of the top 20 diseases related to Fallopian Tube Carcinoma:

Diseases related to Fallopian Tube Carcinoma

Symptoms & Phenotypes for Fallopian Tube Carcinoma

GenomeRNAi Phenotypes related to Fallopian Tube Carcinoma according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased homologous recombination repair frequency GR00151-A-1 10.32 BARD1 BRCA1
2 Decreased homologous recombination repair frequency GR00151-A-2 10.32 BRCA1
3 Decreased homologous recombination repair frequency GR00236-A-3 10.32 BARD1 BRCA1 BRCA2
4 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.96 BARD1 BRCA1 BRCA2 RAD51D TP53
5 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.96 BARD1 BRCA1 BRCA2 RAD51D TP53
6 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.65 BARD1 BRCA1 BRCA2 RAD51D TP53
7 Decreased viability with cisplatin GR00101-A-4 9.5 BARD1 BRCA1 BRCA2
8 Synthetic lethal with cisplatin GR00101-A-1 9.33 BARD1 BRCA1 BRCA2
9 Upregulation of Wnt/beta-catenin pathway after WNT3A stimulation GR00016-A 8.92 BARD1 BRCA1 BRCA2 RAD51D

MGI Mouse Phenotypes related to Fallopian Tube Carcinoma:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.16 BARD1 BRCA1 BRCA2 CAPG ERBB2 PGR
2 embryo MP:0005380 10.08 BARD1 BRCA1 BRCA2 ERBB2 PGR RAD51D
3 mortality/aging MP:0010768 9.97 BARD1 BRCA1 BRCA2 ERBB2 PGR RAD51D
4 limbs/digits/tail MP:0005371 9.95 BRCA1 BRCA2 ERBB2 PGR RAD51D TP53
5 endocrine/exocrine gland MP:0005379 9.93 BRCA1 BRCA2 ERBB2 PGR TP53 VEGFA
6 integument MP:0010771 9.91 BRCA1 BRCA2 ERBB2 PGR TP53 VEGFA
7 digestive/alimentary MP:0005381 9.89 BRCA1 BRCA2 ERBB2 TP53 VEGFA
8 neoplasm MP:0002006 9.87 BARD1 BRCA1 BRCA2 ERBB2 PGR TP53
9 nervous system MP:0003631 9.8 BARD1 BRCA1 BRCA2 ERBB2 RAD51D TP53
10 normal MP:0002873 9.7 BARD1 BRCA1 BRCA2 ERBB2 PGR TP53
11 reproductive system MP:0005389 9.43 BRCA1 BRCA2 ERBB2 PGR TP53 VEGFA
12 skeleton MP:0005390 9.1 BRCA1 BRCA2 ERBB2 PGR TP53 VEGFA

Drugs & Therapeutics for Fallopian Tube Carcinoma

Drugs for Fallopian Tube Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 370)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Olaparib Approved Phase 4 763113-22-0 23725625
2 Poly(ADP-ribose) Polymerase Inhibitors Phase 4
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
Cisplatin Approved Phase 2, Phase 3 15663-27-1 84093 441203 2767
Ifosfamide Approved Phase 2, Phase 3 3778-73-2 3690
Sodium citrate Approved, Investigational Phase 3 68-04-2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
Epirubicin Approved Phase 3 56420-45-2 41867
Alvimopan Approved, Investigational Phase 3 156053-89-3 5488548
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
Durvalumab Approved, Investigational Phase 3 1428935-60-7
nivolumab Approved Phase 3 946414-94-4
Trabectedin Approved, Investigational Phase 3 114899-77-3 108150
leucovorin Approved Phase 3 58-05-9 143 6006
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
Rucaparib Approved, Investigational Phase 3 283173-50-2 9931954
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 3 65-23-6 1054
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 3 53-43-0 9860744
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
Saracatinib Investigational Phase 2, Phase 3 379231-04-6
25 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
26 Paclitaxel poliglumex Experimental, Investigational Phase 3 263351-82-2
Cediranib Investigational Phase 3 288383-20-0 9933475
Maleic acid Experimental, Investigational Phase 3 110-17-8, 110-16-7 444972
Trebananib Investigational Phase 3 894356-79-7
Fosbretabulin Investigational Phase 2, Phase 3 222030-63-9 5351387
31 Combretastatin Investigational Phase 2, Phase 3 82855-09-2
32 Antineoplastic Agents, Phytogenic Phase 3
33 Tubulin Modulators Phase 3
34 Albumin-Bound Paclitaxel Phase 3
35 Antimitotic Agents Phase 3
Isophosphamide mustard Phase 2, Phase 3 0
37 Analgesics Phase 3
38 Peripheral Nervous System Agents Phase 3
39 Citrate Phase 3
Erlotinib Hydrochloride Phase 3 183319-69-9 176871
41 Gastrointestinal Agents Phase 3
42 Epothilone B Phase 3
43 Liver Extracts Phase 3
44 Anesthetics, Intravenous Phase 3
45 Narcotics Phase 3
46 Adjuvants, Anesthesia Phase 3
47 Central Nervous System Depressants Phase 3
48 Anesthetics Phase 3
49 Anesthetics, General Phase 3
50 Analgesics, Opioid Phase 3

Interventional clinical trials:

(show top 50) (show all 641)
# Name Status NCT ID Phase Drugs
1 An Open Label, Single Arm, Multicentre Study to Assess the Clinical Effectiveness and Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed Somatic or Germline BRCA Mutated Ovarian Cancer Patients Who Are in Complete or Partial Response Following Platinum Based Chemotherapy (ORZORA). Active, not recruiting NCT02476968 Phase 4 Olaparib
2 A Randomized Phase II/III Trial Comparing Carboplatin-Ifosfamide (IC)-Chemotherapy Vs. IC-Chemotherapy Combined With Extreme Whole Body Hyperthermia In Patients With Recurrence Of Epithelial Ovarian Carcinoma: DOLPHIN-1-STUDY Unknown status NCT00045461 Phase 2, Phase 3 carboplatin;ifosfamide
3 Randomized Phase III Trial of Conventional Paclitaxel and Carboplatin Versus Dose Dense Weekly Paclitaxel and Carboplatin in Patients With Newly Diagnosed Stage II-IV Mullerian Carcinoma Unknown status NCT00226915 Phase 3 Paclitaxel+Carboplatin;Paclitaxel+Carboplatin
4 A Randomised, Placebo-controlled, Trial of Concurrent Cediranib [AZD2171] (With Platinum-based Chemotherapy) and Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer Unknown status NCT00532194 Phase 3 cediranib
5 An International Phase III Randomised Trial of Dose Fractionated Chemotherapy Compared to Standard Three Weekly Chemotherapy, Following Immediate Primary Surgery or as Part of Delayed Primary Surgery, for Women With Newly Diagnosed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Unknown status NCT01654146 Phase 3 Carboplatin;Carboplatin;Paclitaxel;Paclitaxel
6 A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary Unknown status NCT00954174 Phase 3 Carboplatin;Ifosfamide;Paclitaxel
7 The Phase II Study of Intraoperative Hyperthermic Intraperitoneal Chemotherapy Followed by Intravenous Chemotherapy in Patients With Ovarian Cancer Unknown status NCT01091636 Phase 2, Phase 3
8 Stage IIIC Unresectable Epithelial Ovarian/Tubal Cancer With Partial or Complete Response After 1st Line Neoadjuvant Chemotherapy (3 Cycles CBDCA+Paclitaxel): a Phase 3 Prospective Randomized Study Comparing Cytoreductive Surgery + Hyperthermic Intraperitoneal Chemotherapy (CDDP+Paclitaxel) + 3 Cycles CBDCA+Paclitaxel vs Cytoreductive Surgery Alone + 3 Cycles CBDCA+Paclitaxel. Unknown status NCT01628380 Phase 3
9 A Phase III, Multicenter, Randomized, Blinded, Placebo-controlled Trial of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Platinum-sensitive Recurrent Ovary, Primary Peritoneal, or Fallopian Tube Carcinoma Completed NCT00434642 Phase 3 Carboplatin;Gemcitabine;Bevacizumab;Placebo
10 A Randomized Feasibility Trial to Determine the Impact of Timing of Surgery and Chemotherapy in Newly Diagnosed Patients With Advanced Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Carcinoma Completed NCT00075712 Phase 2, Phase 3 carboplatin;paclitaxel
11 A Randomized Study Of Tamoxifen Versus Thalidomide (NSC# 66847) In Patients With Biochemical-Recurrence-Only Epithelial Ovarian Cancer, Cancer Of The Fallopian Tube, And Primary Peritoneal Carcinoma After First Line Chemotherapy Completed NCT00041080 Phase 3 tamoxifen citrate;thalidomide
12 A Randomized Phase III Study Comparing Upfront Debulking Surgery Versus Neo-Adjuvant Chemotherapy in Patients With Stage IIIC or IV Epithelial Ovarian Carcinoma Completed NCT00003636 Phase 3 carboplatin;cisplatin
13 A Phase 3, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers Completed NCT01204749 Phase 3 AMG 386;AMG 386 Placebo;Paclitaxel;Paclitaxel
14 A Randomized, Multicenter, Phase III Study of Erlotinib Versus Observation in Patients With no Evidence of Disease Progression After First Line, Platinum-Based Chemotherapy For High-Risk Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00263822 Phase 3 erlotinib hydrochloride
15 A Randomized, Parallel Group, Open-label, Active Controlled, Multicenter Phase III Trial of Patupilone (EPO906) Versus Pegylated Liposomal Doxorubicin in Taxane/Platinum Refractory/Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian or Primary Peritoneal Cancer Completed NCT00262990 Phase 3 EPO906 (Patupilone);doxorubicin
16 Multi-Center, Randomized, Double-Blind, Phase III Efficacy Study Comparing Phenoxodiol in Combination With Carboplatin Versus Carboplatin With Placebo in Patients With Platinum-Resistant or Platinum-Refractory Late-Stage Epithelial Ovarian, Fallopian or Primary Peritoneal Cancer Following at Least Second Line Platinum Therapy Completed NCT00382811 Phase 3 phenoxodiol;carboplatin;placebo
17 A Multi-National Randomized Phase-III GCIG Intergroup-Study Comparing 1st-line Chemotherapy With Gemcitabine/Paclitaxel/Carboplatin vs Paclitaxel/Carboplatin In Previously Untreated Patients With Epithelial Ovarian Cancer FIGO Stages I-IV Completed NCT00052468 Phase 3 TCG;TC
18 ICON7 - A Randomised, Two-Arm, Multi-Centre Gynaecologic Cancer InterGroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin and Paclitaxel) in Patients With Epithelial Ovarian Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
19 A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT01846611 Phase 3 Trabectedin;DOXIL;Dexamethasone;DOXIL
20 Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00850772 Phase 3
21 An Open, Randomized, Multicenter Study in Patients With Recurrent Epithelian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer to Compare the Efficay and Safety of Paclitaxel (Micellar) Nanoparticles and Paclitaxel (Cremophor® EL) Completed NCT00989131 Phase 3 Paclical®;Taxol®
22 Phase III Randomized Trial of Induction Chemotherapy With Gemcitabine and Carboplatin Followed by Elective Paclitaxel Consolidation Versus Paclitaxel and Carboplatin Followed by Elective Paclitaxel Consolidation in Patients With Primary Epithelial Ovarian, Primary Peritoneal Cancer or Fallopian Tube Carcinoma Completed NCT00191646 Phase 3 Gemcitabine;Paclitaxel;Carboplatin
23 Phase III Multicenter Study in Epithelial Ovarian Carcinoma FIGO Stage IIB-IV Comparing Treatment With Paclitaxel and Carboplatin to Paclitaxel and Carboplatin Sequentially Followed by Topotecan Completed NCT00006454 Phase 3 carboplatin;paclitaxel;topotecan hydrochloride
24 SCOTROC 4: A Prospective, Multicentre, Randomised Trial Of Carboplatin Flat Dosing Vs Intrapatient Dose Escalation In First Line Chemotherapy Of Ovarian, Fallopian Tube And Primary Peritoneal Cancers Completed NCT00098878 Phase 3 carboplatin
25 Phase III Randomized Trial of 12 Months vs. 3 Months of Paclitaxel in Patients With Advanced Ovarian Cancer Who Attain a Clinically Defined Complete Response (CR) Following Platinum/Paclitaxel-Based Chemotherapy Completed NCT00003120 Phase 3 paclitaxel
26 A Randomised Trial in Relapsed Ovarian Cancer: Early Treatment Based on CA 125 Levels Alone Vs. Delayed Treatment Based On Conventional Clinical Indicators Completed NCT00002895 Phase 3 chemotherapy
27 A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
28 A Randomized Trial of Paclitaxel/Epirubicin/Carboplatin Combination (TEC) Versus Paclitaxel/Carboplatin (TC) in the Treatment of Women With Advanced Ovarian Cancer Completed NCT00004934 Phase 3 carboplatin;epirubicin hydrochloride;paclitaxel
29 A Double-Blind Randomized Trial of Pyridoxine Versus Placebo for the Prevention of Doxil-Related Palmar-Plantar Erythrodysesthesia (Hand-Foot Syndrome) Completed NCT00245050 Phase 3 Placebo;doxorubicin HCL liposome
30 The Use of Glutathione (GSH) for Prevention of Paclitaxel/Carboplatin (TAXOL/CBDCA) Induced Peripheral Neuropathy: A Phase III Randomized, Double-Blind Placebo Controlled Study Completed NCT02311907 Phase 3 Carboplatin;Glutathione;Paclitaxel
31 Accelerating Gastrointestinal Recovery in Women Undergoing Staging and/or Debulking Surgery for Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma: A Randomized, Double-Blind, Placebo-Controlled Trial Completed NCT01704651 Phase 3 Alvimopan;Placebo
32 Phase III Randomized Study of TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Liposomal Doxorubicin (Doxil) as Second-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer [ASSIST-3] Completed NCT00102973 Phase 3 TLK286 in Combination with Carboplatin;Doxorubicin HCl Liposome Injection
33 Global Study to Assess the Addition of Bevacizumab to Carboplatin and Paclitaxel as Front-line Treatment of Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma Completed NCT01239732 Phase 3 Paclitaxel;Bevacizumab;Carboplatin
34 A Randomized Phase III Trial of Gemzar Versus Doxil With Crossover Treatment Option for Patients With Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer Undergoing Second or Third-Line Chemotherapy Completed NCT00191607 Phase 3 Gemcitabine;liposomal doxorubicin
35 A Randomized Study of Chemotherapy Versus Hormonal Treatment in Patients With Ovarian Cancer Resistant or Refractory to Platinum and Taxane Completed NCT02728622 Phase 3 Tamoxifen;Chemotherapy
36 A Multi-National,Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin and Carboplatin Versus Paclitaxel and Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse (> 6 Months) Completed NCT00189553 Phase 3 Pegylated liposomal doxorubicin;Carboplatin;Paclitaxel
37 A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed After First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00866697 Phase 3 Pazopanib;Placebo
38 A Randomised Placebo-controlled Trial of Saracatinib (AZD0530) Plus Weekly Paclitaxel in Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed NCT01196741 Phase 2, Phase 3 Paclitaxel;Saracatinib;Matched placebo
39 Phase III Double-Blind Study Of Depot Octreotide Versus Placebo In The Prevention Of Acute Diarrhea In Patients Receiving Pelvic Radiation Therapy Completed NCT00033605 Phase 3 octreotide acetate
40 Vaginal DHEA for Vaginal Symptoms: A Phase III Randomized, Double Blind, Placebo- Controlled Trial Completed NCT01376349 Phase 3 prasterone
41 Application of the Microculture Kinetic (MiCK) Assay for Apoptosis to Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas Completed NCT00443196 Phase 2, Phase 3
42 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
43 Study of Upfront Surgery Versus Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery for Patients With Stage IIIC and IV Ovarian Cancer Recruiting NCT02859038 Phase 3
44 ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02855944 Phase 3 Chemotherapy;Rucaparib
45 A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (KEYLYNK-001/ENGOT-ov43) Recruiting NCT03740165 Phase 3 Placebo for pembrolizumab;Carboplatin;Paclitaxel;Olaparib;Placebo for olaparib
46 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase III Clinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) for Maintenance Treatment in Patients With Platinum-sensitive Relapsed Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer (Collectively Referred to as Ovarian Cancer) Recruiting NCT03705156 Phase 3 ZL-2306(nirapairb);Placebos
47 Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma : Randomized Clinical Trial. Recruiting NCT02328716 Phase 3 Hipec with Cisplatin
48 Evaluation of Secondary Cytoreductive Surgery in Platinum-Sensitive Recurrent Ovarian Cancer: A Phase III, Multicenter, Randomized Trial Recruiting NCT01611766 Phase 3 Salvage Chemotherapy
49 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase III Clinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) for Maintenance Treatment in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer (Collectively Referred to as Ovarian Cancer) Who Have Achieved Effective Response After First-line Platinum-containing Chemotherapy Recruiting NCT03709316 Phase 3 ZL-2306 (Nirapairb);Placebo Comparator
50 A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) Recruiting NCT02502266 Phase 2, Phase 3 Cediranib;Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan;Topotecan Hydrochloride

Search NIH Clinical Center for Fallopian Tube Carcinoma

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Cochrane evidence based reviews: fallopian tube neoplasms

Genetic Tests for Fallopian Tube Carcinoma

Genetic tests related to Fallopian Tube Carcinoma:

# Genetic test Affiliating Genes
1 Neoplasm of Fallopian Tube 29
2 Carcinoma of Fallopian Tube 29

Anatomical Context for Fallopian Tube Carcinoma

MalaCards organs/tissues related to Fallopian Tube Carcinoma:

Ovary, Breast, Testes, T Cells, Uterus, Colon, Smooth Muscle

The Foundational Model of Anatomy Ontology organs/tissues related to Fallopian Tube Carcinoma:

Fallopian Tube

Publications for Fallopian Tube Carcinoma

Articles related to Fallopian Tube Carcinoma:

(show top 50) (show all 681)
# Title Authors PMID Year
Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. 9 38
19141781 2009
Occult fallopian tube cancer in a patient with BRCA1 breast cancer. 9 38
18971141 2008
Microinvasive fimbrial fallopian tube carcinoma in a BRCA-2 mutation carrier. 9 38
18207147 2008
Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. 9 38
16835424 2006
Follow-up of in situ and early-stage fallopian tube carcinoma in patients undergoing prophylactic surgery for proven or suspected BRCA-1 or BRCA-2 mutations. 9 38
15252324 2004
BRCA2 germline mutations in primary cancer of the fallopian tube. 9 38
15254695 2004
Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. 9 38
15083174 2004
Occult cancer of the fallopian tube in a BRCA2 germline mutation carrier at prophylactic salpingo-oophorectomy. 9 38
14984974 2004
[Carcinoma of the fallopian tube after prophylactic laparoscopic ovariectomy in a patient with a BRCAI mutation]. 9 38
12756880 2003
Incidental diagnosis of primary fallopian tube carcinoma during prophylactic salpingo-oophorectomy in BRCA2 mutation carrier. 9 38
12504983 2002
Pathologic findings in prophylactic oophorectomy specimens in high-risk women. 9 38
12468342 2002
Molecular evidence for putative tumour suppressor genes on chromosome 13q specific to BRCA1 related ovarian and fallopian tube cancer. 9 38
12354934 2002
Inactivation of BRCA1 and BRCA2 in ovarian cancer. 9 38
12237285 2002
Fallopian tube cancer in a BRCA1 mutation carrier: rapid development and failure of screening. 9 38
11810084 2002
A genetic epidemiological study of carcinoma of the fallopian tube. 9 38
11263928 2001
Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. 9 38
11161856 2001
Germline BRCA2 mutation in a patient with fallopian tube carcinoma: a case report. 9 38
10785486 2000
Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. 9 38
10620440 2000
BRCA1 mutations in familial ovarian cancer. 9 38
10444347 1999
TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7). 38
31420412 2019
Quality of life outcomes following surgery for advanced ovarian cancer: a systematic review and meta-analysis. 38
31273066 2019
The first Japanese nationwide multicenter study of BRCA mutation testing in ovarian cancer: CHARacterizing the cross-sectionaL approach to Ovarian cancer geneTic TEsting of BRCA (CHARLOTTE). 38
31263023 2019
Fallopian Tube Carcinoma. 38
31283415 2019
Medical diligence uncovers fallopian tube cancer after abnormal Pap test. 38
31345832 2019
Rapidly Changing Landscape of Fallopian Tube Carcinoma. 38
31283416 2019
Phase II Trial of Chemopreventive Effects of Levonorgestrel on Ovarian and Fallopian Tube Epithelium in Women at High Risk for Ovarian Cancer: An NRG Oncology Group/GOG Study. 38
31015198 2019
Evaluation of screening and risk-reducing surgery for women followed in a high-risk breast/ovarian cancer clinic: it is all about the tubes in BRCA mutation carriers. 38
30775416 2019
[Management of epithelial ovarian cancer. Short text drafted from the French joint recommendations of FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY and endorsed by INCa]. 38
30850152 2019
A patient-centered mobile health application to motivate use of genetic counseling among women with ovarian cancer: A pilot randomized controlled trial. 38
30718125 2019
TNM classification of gynaecological malignant tumours, eighth edition: changes between the seventh and eighth editions. 38
30668753 2019
Sectioning and extensively examining the fimbriated end (SEE-FIM) of the fallopian tube in routine practices, is it worth the effort? 38
30506766 2019
Spontaneous resolution of dermatomyositis associated with fallopian-tube carcinoma following staging surgery: A case report. 38
30855437 2019
An oncoinformatics study to predict the inhibitory potential of recent FDA-approved anti-cancer drugs against human Polo-like kinase 1 enzyme: a step towards dual-target cancer medication. 38
30800581 2019
Ocular Toxicity of Mirvetuximab. 38
30379722 2019
Disparities in health-related quality of life in women undergoing treatment for advanced ovarian cancer: the role of individual-level and contextual social determinants. 38
30003341 2019
GEICO1601-ROLANDO: a multicentric single arm Phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer. 38
30820349 2019
[Part I drafted from the short text of the French Guidelines entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY and endorsed by INCa. (Diagnosis management, surgery, perioperative care, and pathological analysis)]. 38
30686724 2019
Dose-dense cisplatin with gemcitabine for relapsed platinum-resistant ovarian cancer. 38
30674568 2019
Trials in progress: IMagyn050/GOG 3015/ENGOT-OV39. A Phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer. 38
30630885 2019
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. 38
30345884 2018
The Sign of Leser-Trelát and Malignant Acanthosis Nigricans Associated With Fallopian Tube Carcinoma. 38
30303917 2018
Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. 38
30093227 2018
Diagnostic and prognostic value of HE4 in female patients with primary peritoneal carcinoma. 38
30238835 2018
Clinicopathologic features and BRCA mutations in primary fallopian tube cancer in Japanese women. 38
29982601 2018
Successful diagnosis of an occult fallopian tube carcinoma detected from the diaphragm metastasis. 38
29327265 2018
Combined symptom index and second-generation multivariate biomarker test for prediction of ovarian cancer in patients with an adnexal mass. 38
29929922 2018
Efficacy of weekly administration of paclitaxel and carboplatin for advanced ovarian cancer patients with poor performance status. 38
29572761 2018
Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation. 38
29793803 2018
FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer. 38
29424243 2018
Reported Incidence and Survival of Fallopian Tube Carcinomas: A Population-Based Analysis From the North American Association of Central Cancer Registries. 38
29281053 2018

Variations for Fallopian Tube Carcinoma

Cosmic variations for Fallopian Tube Carcinoma:

9 (show top 50) (show all 104)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM10663 TP53 ovary,NS,carcinoma,adenocarcinoma c.916C>T p.R306* 17:7673704-7673704 6
2 COSM10738 TP53 ovary,NS,carcinoma,adenocarcinoma c.542G>A p.R181H 17:7675070-7675070 6
3 COSM11148 TP53 ovary,NS,carcinoma,adenocarcinoma c.476C>T p.A159V 17:7675136-7675136 6
4 COSM11582 TP53 ovary,NS,carcinoma,adenocarcinoma c.395A>G p.K132R 17:7675217-7675217 6
5 COSM11066 TP53 ovary,NS,carcinoma,adenocarcinoma c.578A>T p.H193L 17:7674953-7674953 6
6 COSM6904336 TNFAIP3 ovary,NS,carcinoma,adenocarcinoma c.940G>A p.V314I 6:137877210-137877210 6
7 COSM14135 SMAD4 ovary,NS,carcinoma,adenocarcinoma c.1051G>C p.D351H 18:51065518-51065518 6
8 COSM6904335 SMAD2 ovary,NS,carcinoma,adenocarcinoma c.785-1G>C p.? 18:47848688-47848688 6
9 COSM6904334 RET ovary,NS,carcinoma,adenocarcinoma c.3253A>G p.T1085A 10:43128177-43128177 6
10 COSM6904339 PTCH1 ovary,NS,carcinoma,adenocarcinoma c.3074G>A p.R1025H 9:95458107-95458107 6
11 COSM94978 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.1034A>T p.N345I 3:179203764-179203764 6
12 COSM770 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.2725T>C p.F909L 3:179230062-179230062 6
13 COSM21446 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.3012G>T p.M1004I 3:179234169-179234169 6
14 COSM746 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.263G>A p.R88Q 3:179199088-179199088 6
15 COSM766 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.1636C>A p.Q546K 3:179218306-179218306 6
16 COSM580 NRAS ovary,NS,carcinoma,adenocarcinoma c.181C>A p.Q61K 1:114713909-114713909 6
17 COSM564 NRAS ovary,NS,carcinoma,adenocarcinoma c.35G>A p.G12D 1:114716126-114716126 6
18 COSM522 KRAS ovary,NS,carcinoma,adenocarcinoma c.35G>C p.G12A 12:25245350-25245350 6
19 COSM14065 ERBB2 ovary,NS,carcinoma,adenocarcinoma c.2524G>A p.V842I 17:39725079-39725079 6
20 COSM6224 EGFR ovary,NS,carcinoma,adenocarcinoma c.2573T>G p.L858R 7:55191822-55191822 6
21 COSM53230 EGFR ovary,NS,carcinoma,adenocarcinoma c.2597A>G p.E866G 7:55191846-55191846 6
22 COSM28511 EGFR ovary,NS,carcinoma,adenocarcinoma c.2108T>C p.L703P 7:55173967-55173967 6
23 COSM53225 EGFR ovary,NS,carcinoma,adenocarcinoma c.2112G>A p.L704L 7:55173971-55173971 6
24 COSM53232 EGFR ovary,NS,carcinoma,adenocarcinoma c.2122A>G p.K708E 7:55173981-55173981 6
25 COSM53226 EGFR ovary,NS,carcinoma,adenocarcinoma c.2099A>G p.N700S 7:55173958-55173958 6
26 COSM53266 EGFR ovary,NS,carcinoma,adenocarcinoma c.2165C>T p.A722V 7:55174024-55174024 6
27 COSM53224 EGFR ovary,NS,carcinoma,adenocarcinoma c.2173A>G p.T725A 7:55174032-55174032 6
28 COSM53213 EGFR ovary,NS,carcinoma,adenocarcinoma c.2604A>T p.E868D 7:55191853-55191853 6
29 COSM53229 EGFR ovary,NS,carcinoma,adenocarcinoma c.2232C>A p.I744I 7:55174769-55174769 6
30 COSM53231 EGFR ovary,NS,carcinoma,adenocarcinoma c.2559C>T p.I853I 7:55191808-55191808 6
31 COSM12373 EGFR ovary,NS,carcinoma,adenocarcinoma c.2159C>T p.S720F 7:55174018-55174018 6
32 COSM53265 EGFR ovary,NS,carcinoma,adenocarcinoma c.2556G>T p.K852N 7:55191805-55191805 6
33 COSM22992 EGFR ovary,NS,carcinoma,adenocarcinoma c.2161G>A p.G721S 7:55174020-55174020 6
34 COSM53264 EGFR ovary,NS,carcinoma,adenocarcinoma c.2174C>T p.T725M 7:55174033-55174033 6
35 COSM53235 EGFR ovary,NS,carcinoma,adenocarcinoma c.2481C>T p.Y827Y 7:55191730-55191730 6
36 COSM28286 EGFR ovary,NS,carcinoma,adenocarcinoma c.2494C>T p.R832C 7:55191743-55191743 6
37 COSM53228 EGFR ovary,NS,carcinoma,adenocarcinoma c.2123A>G p.K708R 7:55173982-55173982 6
38 COSM53227 EGFR ovary,NS,carcinoma,adenocarcinoma c.2506C>A p.R836S 7:55191755-55191755 6
39 COSM22499 ATM ovary,NS,carcinoma,adenocarcinoma c.1810C>T p.P604S 11:108252824-108252824 6
40 COSM6904304 AR ovary,NS,carcinoma,adenocarcinoma c.2179C>T p.R727C 23:67717483-67717483 6
41 COSM159008 AKT1 ovary,NS,carcinoma,adenocarcinoma c.235C>A p.Q79K 14:104776711-104776711 6
42 COSM6904337 TSC1 endometrium,NS,carcinoma,adenocarcinoma c.2698C>G p.Q900E 9:132897538-132897538 3
43 COSM10709 TP53 endometrium,NS,carcinoma,adenocarcinoma c.722C>G p.S241C 17:7674241-7674241 3
44 COSM44063 TP53 endometrium,NS,carcinoma,adenocarcinoma c.389T>G p.L130R 17:7675223-7675223 3
45 COSM10704 TP53 endometrium,NS,carcinoma,adenocarcinoma c.844C>T p.R282W 17:7673776-7673776 3
46 COSM11073 TP53 endometrium,NS,carcinoma,adenocarcinoma c.1024C>T p.R342* 17:7670685-7670685 3
47 COSM44622 TP53 endometrium,NS,carcinoma,adenocarcinoma c.694A>G p.I232V 17:7674269-7674269 3
48 COSM10654 TP53 endometrium,NS,carcinoma,adenocarcinoma c.637C>T p.R213* 17:7674894-7674894 3
49 COSM45035 TP53 endometrium,NS,carcinoma,adenocarcinoma c.761T>G p.I254S 17:7674202-7674202 3
50 COSM43545 TP53 endometrium,NS,carcinoma,adenocarcinoma c.503A>G p.H168R 17:7675109-7675109 3

Expression for Fallopian Tube Carcinoma

Search GEO for disease gene expression data for Fallopian Tube Carcinoma.

Pathways for Fallopian Tube Carcinoma

Pathways related to Fallopian Tube Carcinoma according to GeneCards Suite gene sharing:

(show all 35)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
12.77 TP53 RAD51D BRCA1 BARD1
Show member pathways
12.72 TP53 BRCA2 BRCA1 BARD1
Show member pathways
8 12.62 VEGFA TP53 ERBB2 BRCA2
Show member pathways
12.61 TP53 PSMB4 BRCA1 BARD1
Show member pathways
12.44 TP53 PSMB4 BRCA1 BARD1
Show member pathways
Show member pathways
13 12.35 VEGFA TP53 ERBB2 BRCA1
Show member pathways
Show member pathways
12.19 TP53 BRCA1 BARD1
16 12.11 VEGFA TP53 ERBB2
Show member pathways
Show member pathways
12.06 TP53 PSMB4 BRCA1
19 11.87 VEGFA TP53 PSMB4
20 11.59 TP53 ERBB2 BRCA1
21 11.58 VEGFA TP53 ERBB2
22 11.53 VEGFA TP53 PSMB4
23 11.52 TP53 ERBB2 BRCA1
24 11.39 VEGFA TP53 BRCA1
25 11.32 TP53 BRCA1 BARD1
26 11.31 TP53 BRCA2 BRCA1 BARD1
27 11.28 TP53 BRCA1 BARD1
28 11.24 BRCA1 BARD1
29 11.22 VEGFA TP53
Show member pathways
11.18 TP53 BRCA2 BRCA1 BARD1
32 11.14 TP53 BRCA1
33 11.12 TP53 BRCA1
34 10.86 TP53 BRCA1
35 10.79 TP53 BRCA1 BARD1

GO Terms for Fallopian Tube Carcinoma

Cellular components related to Fallopian Tube Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.76 TP53 RAD51D PSMB4 PGR CAPG BRCA2
2 cytoplasm GO:0005737 9.65 VEGFA TP53 RAD51D PSMB4 PGR ERBB2
3 lateral element GO:0000800 9.32 BRCA2 BRCA1
4 BRCA1-A complex GO:0070531 9.26 BRCA1 BARD1
5 BRCA1-BARD1 complex GO:0031436 8.62 BRCA1 BARD1
6 nucleus GO:0005634 10.02 TP53 RAD51D PSMB4 PGR ERBB2 CAPG

Biological processes related to Fallopian Tube Carcinoma according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.76 VEGFA TP53 ERBB2 BRCA1
2 DNA repair GO:0006281 9.71 RAD51D BRCA2 BRCA1 BARD1
3 negative regulation of apoptotic process GO:0043066 9.67 VEGFA TP53 BARD1
4 DNA recombination GO:0006310 9.61 RAD51D BRCA2 BRCA1
5 response to gamma radiation GO:0010332 9.56 TP53 BRCA2
6 protein deubiquitination GO:0016579 9.56 TP53 PSMB4 BRCA1 BARD1
7 chromosome organization GO:0051276 9.55 RAD51D BRCA2
8 cell aging GO:0007569 9.54 TP53 BRCA2
9 positive regulation of cell cycle arrest GO:0071158 9.52 TP53 BRCA1
10 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 9.51 TP53 BRCA2
11 double-strand break repair via homologous recombination GO:0000724 9.5 RAD51D BRCA2 BRCA1
12 DNA double-strand break processing GO:0000729 9.48 BRCA1 BARD1
13 protein K6-linked ubiquitination GO:0085020 9.37 BRCA1 BARD1
14 cellular response to DNA damage stimulus GO:0006974 9.35 TP53 RAD51D BRCA2 BRCA1 BARD1
15 mammary gland development GO:0030879 9.27 PGR
16 chordate embryonic development GO:0043009 9.16 BRCA2 BRCA1
17 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.8 TP53 BRCA2 BRCA1

Molecular functions related to Fallopian Tube Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.85 VEGFA TP53 RAD51D PSMB4 PGR ERBB2
2 gamma-tubulin binding GO:0043015 9.26 RAD51D BRCA2
3 protein heterodimerization activity GO:0046982 9.26 VEGFA TP53 ERBB2 BARD1
4 identical protein binding GO:0042802 9.1 VEGFA TP53 PGR ERBB2 BRCA2 BRCA1

Sources for Fallopian Tube Carcinoma

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
71 Tocris
73 UMLS via Orphanet
Loading form....